Apogee Therapeutics, Inc. · NASDAQ:APGE
Apogee Therapeutics — Technical Presentation (March 2026)
40 slides from Apogee Therapeutics's technical presentation, Mar 23, 2026
Slide 1: APEX Part A 52-week readout
APEX Part A 52-week readout March 23, 2026
Slide 2: Disclaimers and Forward-looking statements
2 © Apogee Therapeutics, Inc. Disclaimers and Forward-looking statements Other than statements of historical facts, all statements included in this presentation are forward-looking statements, including statements about our plans for our current and future product candidates and programs; the antici
Slide 3: Agenda
3 © Apogee Therapeutics, Inc. Agenda Introduction Michael Henderson, MD Chief Executive Officer Carl Dambkowski, MD Chief Medical Officer Kristine Nograles, MD SVP, Head of Clinical Development & Medical Affairs APEX Phase 2 Part A 52-Week Results Zumilokibart Development Program Building a Leading
Slide 4: Introduction
Introduction Michael Henderson, MD Chief Executive Officer
Slide 5: Building a leading I&I company to address Type 2 inflammatory conditions
5 © Apogee Therapeutics, Inc. Building a leading I&I company to address Type 2 inflammatory conditions Atopic dermatitis (AD) is growing rapidly and could be the largest I&I market • AD market is projected to reach $50B+ • New entrants with limited differentiation are quickly becoming blockbusters ©
Slide 6: Data support planned zumilokibart Phase 3 initiation in 2H 2026
6 © Apogee Therapeutics, Inc. APEX PART A Data support planned zumilokibart Phase 3 initiation in 2H 2026 with every 3- and every 6-month dosing regimens Durable maintenance of response at 52 weeks Maintenance of EASI-75: • 75% every 3-month dosing • 85% every 6-month dosing Maintenance of IGA 0/1:
Slide 7: Apogee has the potential to transform the future $50B atopic dermatitis market
7 © Apogee Therapeutics, Inc. 0 2 4 6 8 10 12 24 0 30 40 50 60 70 80 90 Amlitelimab (24-week) Apogee has the potential to transform the future $50B atopic dermatitis market Efficacy (EASI-75 at Week 16, %) APEX PART A NOTE: Positioning of Apogee programs is illustrative and based on Phase 2 Part A r
Slide 8: APEX Part A 52-week results
APEX Part A 52-week results Carl Dambkowski, MD Chief Medical Officer
Slide 9: APEX Part A study design
9 © Apogee Therapeutics, Inc. APEX Part A study design APEX Part A schematic APEX PART A Induction Maintenance Week 0 Week 16 Week 52 720mg W0, W2, 360mg W4, W12 Every 3 months (360mg Q12W) Every 6 months (360mg Q24W) 1:1 Placebo Placebo crossover to zumilokibart crossover dose6 Efficacy analysis po
Slide 10: Baseline characteristics and demographics were in line with expectations
10 © Apogee Therapeutics, Inc. Baseline characteristics and demographics were in line with expectations APEX PART A Baseline demographics and disease characteristics of all patients treated with zumilokibart Characteristic Study mITT population (all patients receiving ≥1 dose of zumilokibart; N=119)
Slide 11: Zumilokibart was well-tolerated across the full 52-week treatment period
11 © Apogee Therapeutics, Inc. APEX PART A Zumilokibart was well-tolerated across the full 52-week treatment period NOTE: Safety data are derived from different clinical trials conducted at different times, with differences in trial design and patient populations. As a result, cross-trial comparison
Slide 12: Conjunctivitis rates comparison
12 © Apogee Therapeutics, Inc. NOTE: Safety data are derived from different clinical trials conducted at different times, with differences in trial design and patient populations. As a result, cross-trial comparisons cannot be made, and no head-to-head clinical trials have been conducted. 1 Conjunct
Slide 13: Zumilokibart achieved durable maintenance of Week 16 responses
Zumilokibart achieved durable maintenance of Week 16 responses
Slide 14: Patients with response at Week 16 assessed for maintenance at Week 52
14 © Apogee Therapeutics, Inc. Patients who achieved a response at Week 16 were assessed for maintenance of response at Week 52 APEX Part A schematic APEX PART A | MAINTENANCE OF RESPONSE 720mg W0, W2, 360mg W4, W12 Induction Every 3 months (360mg Q12W) Every 6 months (360mg Q24W) Maintenance Week 0
Slide 15: Zumilokibart demonstrated 75-85% maintenance of EASI-75 response
15 © Apogee Therapeutics, Inc. Zumilokibart demonstrated 75-85% maintenance of EASI-75 response APEX PART A | MAINTENANCE OF RESPONSE Maintenance of EASI-75 response among patients with EASI-75 at Week 16 (%) 16 20 24 28 32 36 40 44 48 52 0 20 40 60 80 100 Week Every 6 months (Q24W, N=24) Every 3 mo
Slide 16: Zumilokibart demonstrated 78-86% maintenance of IGA 0/1 response
16 © Apogee Therapeutics, Inc. Zumilokibart demonstrated 78-86% maintenance of IGA 0/1 response APEX PART A | MAINTENANCE OF RESPONSE NOTE: For illustrative purposes only. Efficacy data are derived from different clinical trials conducted at different times, with differences in trial design and pati
Slide 17: 82-88% reduction in EASI and 67-77% reduction in Itch NRS among EASI-75 responders
17 © Apogee Therapeutics, Inc. Zumilokibart demonstrated 82-88% reduction in EASI and 67-77% reduction in Itch NRS score among EASI-75 responders APEX PART A | MAINTENANCE OF RESPONSE %CFBL EASI among EASI-75 responders (%) NOTE: For %CFBL EASI, missing data was imputed with Markov Chain Monte Carlo
Slide 18: Zumilokibart led to deepening responses over 52 weeks
Zumilokibart led to deepening responses over 52 weeks
Slide 19: Responses assessed for all patients initially randomized to zumilokibart
19 © Apogee Therapeutics, Inc. Responses over 52 weeks were assessed for all patients who were initially randomized to zumilokibart APEX Part A schematic APEX PART A | OVERALL RESPONSE THROUGH WEEK 52 720mg W0, W2, 360mg W4, W12 Induction Every 3 months (360mg Q12W) Every 6 months (360mg Q24W) Maint
Slide 20: Zumilokibart achieves >99% IL-13 inhibition and deepening of response
20 © Apogee Therapeutics, Inc. Zumilokibart achieves >99% IL-13 inhibition and demonstrates deepening of response on all endpoints SOURCE: DUPIXENT USPI. NOTE: Efficacy data are derived from different clinical trials conducted at different times, with differences in trial design and patient populati
Slide 21: Zumilokibart IGA 0/1 responses deepened by 14-35 percentage points
21 © Apogee Therapeutics, Inc. Zumilokibart IGA 0/1 responses deepened by 14-35 percentage points APEX PART A | OVERALL RESPONSE THROUGH WEEK 52 IGA 0/1 with a Reduction of ≥2 Points from Baseline (%) 0 4 8 12 16 20 24 28 32 36 40 44 48 52 0 20 40 60 80 100 Week Induction (N=82) Every 6 months (Q24W
Slide 22: Zumilokibart Itch-NRS reduction deepened by 13-22 percentage points
22 © Apogee Therapeutics, Inc. Zumilokibart Itch-NRS reduction deepened by 13-22 percentage points APEX PART A | OVERALL RESPONSE THROUGH WEEK 52 %CFBL I-NRS (LS mean) 0 4 8 12 16 20 24 28 32 36 40 44 48 52 0 -80 -60 -40 -20 -100 Week Induction (N=82) Every 6 months (Q24W, N=34) Every 3 months (Q12W
Slide 23: Zumilokibart EASI-75 responses deepened by 6-13 percentage points
23 © Apogee Therapeutics, Inc. Zumilokibart EASI-75 responses deepened by 6-13 percentage points APEX PART A | OVERALL RESPONSE THROUGH WEEK 52 EASI-75 Response (%) 0 4 8 12 16 20 24 28 32 36 40 44 48 52 0 20 40 60 80 100 Week Induction (N=82) Every 6 months (Q24W, N=34) Every 3 months (Q12W, N=36)
Slide 24: Zumilokibart EASI-90 responses deepened by 10-36 percentage points
24 © Apogee Therapeutics, Inc. Zumilokibart EASI-90 responses deepened by 10-36 percentage points APEX PART A | OVERALL RESPONSE THROUGH WEEK 52 EASI-90 Response (%) 0 4 8 12 16 20 24 28 32 36 40 44 48 52 0 20 40 60 80 100 Week Induction (N=82) Every 6 months (Q24W, N=34) Every 3 months (Q12W, N=36)
Slide 25: Zumilokibart EASI-100 responses deepened by 11-33 percentage points
25 © Apogee Therapeutics, Inc. Zumilokibart EASI-100 responses deepened by 11-33 percentage points APEX PART A | OVERALL RESPONSE THROUGH WEEK 52 EASI-100 Response (%) 0 4 8 12 16 20 24 28 32 36 40 44 48 52 0 20 40 60 80 100 Week Induction (N=82) Every 6 months (Q24W, N=34) Every 3 months (Q12W, N=3
Slide 26: Unmet Need in Atopic Dermatitis
Unmet Need in Atopic Dermatitis Ruth Ann Vleugels, MD, MPH, MBA Heidi and Scott C. Schuster Distinguished Chair in Dermatology Director, Atopic Dermatitis Program Brigham & Women’s Hospital Department of Dermatology Professor of Dermatology, Harvard Medical School
Slide 27: Atopic dermatitis is a severe, systemic disease
27 Atopic dermatitis is a severe, systemic disease 1) Primary Care Dermatology Society
Slide 28: Atopic dermatitis has a profound impact on patient quality of life
28 Atopic dermatitis has a profound impact on patient quality of life Children Adults Healthcare system 1) Bridgman et al., 2018. Ann Allergy Asthma Immunol. 2) Irish Skin Foundation. Loss of sleep Absence from school Growth restriction Depression Work sick leave Reduced physical activity Hospitaliz
Slide 29: Approval of new therapies has improved AD care
29 Approval of new therapies has improved AD care Pre-2017 2017 2020 2023 2026 Dupilumab (IL-4Ra) Year of AD approval Tralokinumab (IL-13) Lebrikizumab (IL-13) Nemolizumab (IL-31) Topicals Biologics Oral JAK inhibitors Hydrocortisone & other TCS Roflumilast (PDE4) Ruxolitinib (JAK) Upadacitinib Abro
Slide 30: Despite multiple treatment options for AD, unmet need remains significant
30 Despite multiple available treatment options for AD, unmet need remains significant Therapy Target Strengths Limitations Dupilumab IL-4Ra • Significant lesion benefit • Well tolerated • Dosing frequency (every 2 weeks) Lebrikizumab IL-13 • Significant lesion benefit • Well tolerated • Dosing freq
Slide 31: Zumilokibart could address several unmet needs in AD
31 Zumilokibart could address several unmet needs in AD1 • Although newer therapies have greatly improved the lives of patients with AD, substantial unmet need still exists for therapies that are both safe and effective as well as have the ability to reduce injection burden • Zumilokibart demonstrat
Slide 32: Zumilokibart Development Program
Zumilokibart Development Program Kristine Nograles, MD SVP, Clinical Development & Medical Affairs
Slide 33: Zumilokibart Part B trial design
33 © Apogee Therapeutics, Inc. Zumilokibart Part B trial design Mod-Sev AD: EASI ≥16, vIGA ≥3, BSA ≥10%, up to 20% biologic experienced Induction Maintenance Enrollment complete W16 Primary Endpoint: EASI-75 N = 347 1:1:1:1 NOTE: Phase 3 and launch plans subject to clinical and regulatory outcomes.
Slide 34: ASPIRE and ELEVATE dose-ranging trials could enable indication expansions
34 © Apogee Therapeutics, Inc. Beyond zumilokibart in AD, ASPIRE and ELEVATE dose-ranging trials could enable Phase 3 for multiple blockbuster indication expansions ZUMILOKIBART • Allergic Rhinitis (perennial) • COPD • CRSwNP Respiratory ASPIRE Asthma Phase 2 Plans TBA this year • BP • CSU • Cold In
Slide 35: Building a Leading I&I Company
Building a Leading I&I Company Michael Henderson, MD Chief Executive Officer
Slide 36: Zumilokibart could be the next clearly differentiated first line product in AD
36 © Apogee Therapeutics, Inc. Zumilokibart could be the next clearly differentiated first line product to launch in AD Robust Lesion and Itch Control that Deepens Rapid Itch Relief in 48 Hours NOTE: For illustrative purposes only. Efficacy data are derived from different clinical trials conducted a
Slide 37: Apogee has the potential to become a leader in a future $50B+ market
37 © Apogee Therapeutics, Inc. $0 $5 $10 $15 $20 $25 Global Revenue, $B (estimated share for indication) Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Year 8 Year 9 Year 10 Year 11 Year 12 Year 13 Year 14 Year 15 Year 16 Year 17 Year 18 Year 19 Year 20 Years After First Biologic Launch SOURCE: Ev
Slide 38: 2026 is becoming a transformational year for Apogee
2026 is becoming a transformational year for Apogee Apogee poised for sustained leadership in AD starting with potential zumilokibart launch in 2029 NOTE: 1 Cash, cash equivalents and marketable securities were $902.9 million as of December 31, 2025. 2 APG279 is a combination of zumilokibart and APG
Slide 39: Apogee
Apogee /ˈapəjē/ noun The highest point in the development of something; a climax or culmination
Slide 40: Placebo crossover responses by Week 52
40 © Apogee Therapeutics, Inc. Induction (N=82) Every 6 months (Q24W, N=34)1 Every 3 months (Q12W, N=36)1 Placebo crossover (N=37)2 -91% -86% 0 4 8 12 16 20 24 28 32 36 40 44 48 52 -100 -80 -60 -40 -20 0 Week Percent Change from Baseline (LS Mean) Re-randomization Patients crossing over to zumilokib
Apogee Therapeutics — Technical Presentation (March 2026) on 6ix